

Interim Report, Q2 and H1 2014

August 26, 2014 11:16 AM ET

August 26, 2014

CORTENDO REPORTS RESULTS AND ACTIVITIES FOR THE Q2 AND H1 OF 2014

HIGHLIGHTS - H1'2014 AND POST PERIOD

- First patient enrolled into the NormoCort™ Phase 3 SONICS trial - continued progress on trial implementation. The internal and external NormoCort development team has been further strengthened
- Matthew Pauls recruited as new CEO – effective Aug 25
- Strategic review to further strengthen focus on orphan drugs and metabolic disease
- Net loss for the Group was SEK 8.6 (5.6) million in Q2'2014 (Q2'2013) and SEK 19.8 (9.7) million in H1'2014 (H1'2013), reflecting increased R&D activities
- Cash and cash equivalents amounted to SEK 75.4 million, compared to SEK 31.6 million at 30 June 2013 and SEK 97.1 million at the end of December 2013
- Cortendo is currently preparing for and is targeting an Initial Public Offering and listing on the Oslo Stock Exchange during Q4'2014

For the full report see attached pdf-file.

[wrk0006.pdf](#)